Answers are grounded in this paper and cite their sources.
Lung cancer treatment has been revolutionized by the discovery of somatic mutations in epidermal growth factor receptors (EGFRs) and the development of EGFR tyrosine kinase inhibitors (TKIs). However, in most cases, non-small cell lung cancer (NSCLC) patients who are treated with gefitinib eventually develop resistance. The purpose of this study was to investigate the effect of Aloe vera (L.) Burm. f. (A. vera) extract combined with gefitinib on gefitinib-resistant NSCLC cell lines. The cytotoxicity assay showed that there was a minimal inhibitory effect of A. vera on cell proliferation in A549, PC-9, and H1975 cells, while the combined use of A. vera and gefitinib resulted in a significant inhibitory effect on cell growth in a concentration-dependent manner. Importantly, compared to other cell lines, H1975 proliferation was inhibited by the combined treatment more effectively. The IC50 values at 24 h decreased from 37.92 ± 1.19 to 20.09 ± 1.03 μM for H1975 cells. As a result of the combined treatment of A. vera and gefitinib, the migration ability of H1975 cells was decreased compared with that of the gefitinib group. Moreover, A. vera significantly increased the gefitinib-induced apoptosis in H1975 cells and the combination treatment induced G2/M phase arrest in H1975 cells. Furthermore, the Wnt/β-catenin pathway was inhibited in H1975 cells of the high-concentration combination group, suggesting that A. vera is a potential anticancer therapeutic adjuvant for gefitinib-resistant NSCLC with the EGFR-T790M mutation.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: